In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial

Abstract

Background: Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties. Aims: We evaluated the plasma level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after a 4-week treatment with H1 antihistamines, as well as the risk of asthma after 1.5 years. Study Design: Randomized clinical trial. Methods: Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with 5 mg/day desloratadine and 44 patients under 5 mg/day levocetirizine for 4 weeks. The clinical and biological evaluations were performed before and after treatment and included rhinitis symptoms and total symptoms score, type of sensitization, and plasmatic levels of total IgE, IL-1β, IL-6, IL-8 and TNF-α. Results: IL-8 and TNF-α were significantly increased in patients with PAR compared to healthy volunteers (5.85 vs 3.12, p<0.001 and 2.32 vs 1.06, p<0.001, respectively). Both H1 antihistamines reduce all symptoms of allergic rhinitis, including nasal congestion and the plasmatic level of IL-1β, IL-6, IL-8 and TNF-α, after 4 weeks of treatment. The reduction of cytokine levels was not influenced by patients' age, sex, duration or severity of rhinitis, or type of sensitization. Levocetirizine has a superior effect compared to desloratadine in reducing the rhinitis symptoms and cytokines' level. Twenty eight (32.9%) of the patients presented asthma symptoms after 1.5 years. The occurrence of asthma was influenced by house dust sensitization (OR-14.6; CI 95% 1.8-116.3; p=0.01), but baseline values of cytokines were not predictive factors for its appearance. Conclusion: Levocetirizine and desloratadine as a prolonged therapy reduce plasmatic levels of some proinflammatory cytokines in patients with PAR. Levocetirizine has a better effect on decreasing the symptoms and plasmatic levels of IL-1β and IL-8. (ClinicalTrials. gov Identifier: NCT02507635) Founding: POSDRU and University of Medicine and Pharmacy, Iuliu Haţieganu, Cluj Napoca.

Geraniol suppresses proinflammatory mediators in phorbol 12-myristate 13-acetate with A23187-induced HMC-1 cells

“…As such, AR treatment often involves the use of H1 antihistamines which block histamine release. 17 In our study, our results show that both 80 and 160 μmol/L of geraniol are able to stop histamine release by activated HMC-1 cells. This indirectly indicates that geraniol can inhibit mast cell degranulation.…”

NLRP3 inflammasome: A likely target for the treatment of allergic diseases

“…Another study conducted by Leaker et al analysed whole‐genome expression profiles of AR patients and observed type 2 inflammation upregulation involving IL‐1β. Bocşan et al measured plasma IL‐1β levels in patients with persistent AR after H1 antihistamine treatment and found that H1 antihistamines reduced plasma the IL‐1β levels and symptoms of AR. In an OVA mouse model of induced AR, researchers have shown that the serum concentrations of IL‐1β and the nasal septum levels of caspase‐1 in the OVA group were significantly higher than those in the control group.…”

β‐eudesmol suppresses allergic reactions via inhibiting mast cell degranulation

“…The mast cell activation sites were associated with allergic reaction and IL‐1β production . Antihistamine drugs reduced the pro‐inflammatory markers in the allergic reactions and improved the symptoms . In this study, β‐eudesmol inhibited the PCA reaction and levels of histamine, IgE, IL‐1β, IL‐4, IL‐5, IL‐6, IL‐13, and VEGF in the serum of mice under PCA.…”